title: Capsule Commentary on Duru et al., Adherence to Metformin, Statins, and ACE/ARBs Within the Diabetes Health Plan (DHP).
authors.affiliation: PhRMA Foundation Post Doctoral Fellow in Health Outcomes, Center for Pharmaceutical Outcomes Research (CePOR), Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO, 80045, USA. robert.mcqueen@ucdenver.edu.
authors.forename: R Brett
authors.initials: RB
authors.lastname: McQueen
mesh_terms: D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005260:Female; D006264:Health Benefit Plans, Employee / Q000458:organization & administration*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D008297:Male; D008687:Metformin / Q000627:therapeutic use*; D016903:Drug Monitoring
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008687:Metformin